TY - JOUR
T1 - ICOS deficiency in patients with common variable immunodeficiency
AU - Salzer, Ulrich
AU - Maul-Pavicic, Andrea
AU - Cunningham-Rundles, Charlotte
AU - Urschel, Simon
AU - Belohradsky, Bernd H.
AU - Litzman, Jiri
AU - Holm, Are
AU - Franco, José Luis
AU - Plebani, Alessandro
AU - Hammarstrom, Lennart
AU - Skrabl, Andrea
AU - Schwinger, Wolfgang
AU - Grimbacher, Bodo
N1 - Funding Information:
We thank Dörte Thiel, Judith Deimel, and Cristina Wöllner for excellent technical assistance and the patients' physicians Dr. Mezger and Prof. Dr. Vaith. This work was supported by the Deutsche Forschungsgemeinschaft (DFG) grant GR 1617/3 and SFB 620/project C2 to B.G and by grants from the National Institutes of Health, AI-467320, AI-48693, and contract N01-AI-30070, NIH-NIAID-DAIT 03-22 to C.C.
PY - 2004/12
Y1 - 2004/12
N2 - Common variable immunodeficiency (CVID) is the most frequent clinically significant primary antibody deficiency in man, predisposing to recurrent bacterial infections. Recently, we showed that the homozygous loss of the inducible costimulator (ICOS) on activated T cells may result in an adult onset form of CVID with autosomal recessive inheritance (AR-CVID). We screened 181 sporadic CVID patients and 13 CVID patients from nine families with AR-CVID for mutations in ICOS by genomic DNA sequencing. In the AR-CVID families, the genomic integrity of the ligand for ICOS (ICOS-L) was also evaluated. In two of the nine AR-CVID families, we identified five individuals with ICOS deficiency, carrying the identical large genomic deletion of ICOS as previously described. In the remaining seven AR-CVID families, we subsequently sequenced the coding region of the ICOS ligand but found no mutations. The incidence of ICOS deficiency among patients with CVID is less than 5%. Worldwide, there are now a total of nine patients diagnosed with ICOS deficiency most likely due to a common founder. ICOS-L deficiency could not be identified in families with AR-CVID.
AB - Common variable immunodeficiency (CVID) is the most frequent clinically significant primary antibody deficiency in man, predisposing to recurrent bacterial infections. Recently, we showed that the homozygous loss of the inducible costimulator (ICOS) on activated T cells may result in an adult onset form of CVID with autosomal recessive inheritance (AR-CVID). We screened 181 sporadic CVID patients and 13 CVID patients from nine families with AR-CVID for mutations in ICOS by genomic DNA sequencing. In the AR-CVID families, the genomic integrity of the ligand for ICOS (ICOS-L) was also evaluated. In two of the nine AR-CVID families, we identified five individuals with ICOS deficiency, carrying the identical large genomic deletion of ICOS as previously described. In the remaining seven AR-CVID families, we subsequently sequenced the coding region of the ICOS ligand but found no mutations. The incidence of ICOS deficiency among patients with CVID is less than 5%. Worldwide, there are now a total of nine patients diagnosed with ICOS deficiency most likely due to a common founder. ICOS-L deficiency could not be identified in families with AR-CVID.
KW - CVID
KW - ICOS
KW - Immunodeficiency
UR - http://www.scopus.com/inward/record.url?scp=7044224342&partnerID=8YFLogxK
U2 - 10.1016/j.clim.2004.07.002
DO - 10.1016/j.clim.2004.07.002
M3 - Article
C2 - 15507387
AN - SCOPUS:7044224342
SN - 1521-6616
VL - 113
SP - 234
EP - 240
JO - Clinical Immunology
JF - Clinical Immunology
IS - 3
ER -